Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
SANA

SANA - Sana Biotechnology, Inc. Stock Price, Fair Value and News

8.59USD+0.68 (+8.60%)Market Closed

Market Summary

SANA
USD8.59+0.68
Market Closed
8.60%

SANA Stock Price

View Fullscreen

SANA RSI Chart

SANA Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-5.68

Price/Free Cashflow

-6.4

SANA Price/Earnings (Trailing)

SANA Profitability

Return on Equity

-82.26%

Return on Assets

-45.29%

Free Cashflow Yield

-15.62%

SANA Fundamentals

SANA Earnings

Earnings (TTM)

-308.6M

Earnings Growth (Yr)

-30.87%

Earnings Growth (Qtr)

-21.97%

Breaking Down SANA Revenue

Last 7 days

-20.8%

Last 30 days

-11.6%

Last 90 days

26.3%

Trailing 12 Months

24.3%

How does SANA drawdown profile look like?

SANA Financial Health

Current Ratio

6.07

SANA Investor Care

Shares Dilution (1Y)

15.67%

Diluted EPS (TTM)

-1.53

Tracking the Latest Insider Buys and Sells of Sana Biotechnology, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 05, 2024
bishop hans edgar
acquired
-
-
2,774
-
Mar 08, 2024
yang patrick y
sold
-236,300
9.452
-25,000
-
Feb 08, 2024
arch venture fund x, l.p.
bought
6,000,000
5.5
1,090,910
-
Feb 08, 2024
nelsen robert
bought
6,000,000
5.5
1,090,910
-
Feb 08, 2024
crandell keith
bought
6,000,000
5.5
1,090,910
-
Jan 05, 2024
bishop hans edgar
acquired
-
-
4,901
-
Jan 05, 2024
wilderotter mary agnes
acquired
-
-
1,470
-
Dec 15, 2023
hordo christian
sold
-300,098
4.0013
-75,000
evp, chief business officer
Oct 05, 2023
wilderotter mary agnes
acquired
-
-
2,077
-
Oct 05, 2023
bishop hans edgar
acquired
-
-
6,925
-

1–10 of 50

Which funds bought or sold SANA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 13, 2024
RENAISSANCE TECHNOLOGIES LLC
reduced
-41.41
525,000
1,729,000
-%
May 13, 2024
D.A. DAVIDSON & CO.
new
-
222,000
222,000
-%
May 13, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.85
278,288
472,880
-%
May 13, 2024
Ameritas Investment Partners, Inc.
unchanged
-
54,855
92,660
-%
May 13, 2024
Rafferty Asset Management, LLC
added
13.33
3,173,860
4,959,320
0.02%
May 13, 2024
Nuveen Asset Management, LLC
reduced
-23.82
2,575,500
5,545,880
-%
May 13, 2024
GEODE CAPITAL MANAGEMENT, LLC
added
7.22
14,971,700
24,168,300
-%
May 13, 2024
Skandinaviska Enskilda Banken AB (publ)
added
155
4,904,650
5,834,890
0.03%
May 10, 2024
Mitsubishi UFJ Trust & Banking Corp
sold off
-100
-841,541
-
-%
May 10, 2024
OSAIC HOLDINGS, INC.
added
21.02
4,084
6,160
-%

1–10 of 46

Are Funds Buying or Selling SANA?

Are funds buying SANA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SANA
No. of Funds

Unveiling Sana Biotechnology, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 03, 2024
fmr llc
-
0
SC 13G/A
Mar 07, 2024
baillie gifford & co
4.70%
10,360,620
SC 13G/A
Feb 14, 2024
flagship ventures fund v, l.p.
0.5%
1,035,208
SC 13G/A
Feb 09, 2024
arch venture fund ix, l.p.
22.3%
44,042,500
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 26, 2024
baillie gifford & co
5.15%
10,150,017
SC 13G/A
Apr 26, 2023
fmr llc
-
0
SC 13G
Feb 13, 2023
arch venture fund ix, l.p.
23.1%
44,042,500
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Jan 20, 2023
baillie gifford & co
5.64%
10,764,727
SC 13G/A

Recent SEC filings of Sana Biotechnology, Inc.

View All Filings
Date Filed Form Type Document
May 08, 2024
10-Q
Quarterly Report
May 08, 2024
8-K
Current Report
May 08, 2024
S-8
Employee Benefits Plan
Apr 26, 2024
ARS
ARS
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
DEFA14A
DEFA14A
Apr 18, 2024
8-K
Current Report
Apr 08, 2024
3
Insider Trading
Apr 08, 2024
4
Insider Trading
Apr 03, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Sana Biotechnology, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
48.2B
6.8B
19.54% -2.80%
-8.07
7.03
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.0B
2.0B
0.98% -26.98%
-57.12
9.47
75.20% 68.82%
15.3B
2.5B
-12.72% -14.31%
74.39
6.18
13.74% 186.89%
12.9B
3.8B
6.98% -11.75%
17.35
3.43
8.58% 129.81%
MID-CAP
5.3B
107.9M
6.22% 110.41%
-9.76
48.09
54.84% -28.31%
5.2B
524.1M
-16.95% -51.10%
-12.51
9.96
394.93% 39.61%
3.6B
251.0M
9.36% -4.29%
-12.12
14.31
73.58% -86.73%
2.7B
240.7M
-10.69% -43.90%
-5.82
12.77
-1.03% -213.43%
2.5B
813.8M
-11.38% -29.25%
-1.5K
3.08
56.43% 98.83%
SMALL-CAP
1.9B
411.3M
6.64% 20.67%
29.44
4.66
60.38% -34.49%
1.8B
996.6M
206.31% 55.15%
-4.62
1.85
-26.66% 65.49%
458.7M
881.7K
5.07% 336.18%
-13.59
481.06
-77.61% 33.36%
294.6M
4.9M
3.08% 29.79%
-2.36
60.54
-54.97% 48.23%
15.6M
2.1M
-10.40% 79.21%
-0.67
7.61
-13.45% 69.54%

Sana Biotechnology, Inc. News

Latest updates
Defense World11 May 202408:16 am
Investing.com29 Apr 202407:00 am
Seeking Alpha17 Mar 202407:00 am

Sana Biotechnology, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets20.5%6815656317077478238989711,0481,1291,2331,2601,304730
  Current Assets50.5%321214280339370444500494523558613860967384
    Cash Equivalents35.5%181134168174160177174205197253442677753127
  Net PPE15.5%82.0071.0068.0063.0064.0067.0067.0068.0069.0065.0063.0059.0051.0047.00
  Goodwill0%141141141141141141141141141141141141141141
Liabilities10.2%306278266352319323332332346401403354422299
  Current Liabilities-18.0%53.0064.0067.0011210311211597.0094.0099.0092.0043.0035.0031.00
Shareholder's Equity30.5%375288366355428499566640702729830906882-
  Retained Earnings-11.2%-1,445-1,300-1,249-1,300-1,100-1,054-974-889-816-785-674-591-610-429
  Additional Paid-In Capital12.0%1,8211,6261,6161,6071,5671,5581,5471,5351,5241,5151,5051,4971,4928.00
Shares Outstanding11.8%221198197197191191188188186166161180--
Float----600---1,200---3,700--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Cashflow From Operations-26.3%-65,632-51,959-63,550-58,801-79,272-76,067-64,796-71,478-77,709-110,099-50,486-40,556-49,913-37,559-37,510-33,366-29,547-
  Share Based Compensation14.6%9,0927,9319,0039,8488,75110,59110,0809,9117,7557,3135,9504,9414,1582,7911,1661,116755-
Cashflow From Investing-604.4%-77,22815,31051,34842,62762,72788,42831,85977,73012,545-73,661-185,904-35,32449,09113,041-268,313-36,47239,181-
Cashflow From Financing10749.7%186,3971,71818729,5052361,0611,6211,5796523,1191,596333626,7031034.00435,5782.00-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SANA Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 56,448$ 67,166
Research and development related success payments and contingent consideration38,007120
General and administrative16,26916,766
Total operating expenses110,72484,052
Loss from operations(110,724)(84,052)
Interest income, net3,0341,976
Other income (expense), net215(47)
Net loss$ (107,475)$ (82,123)
Net loss per common share - basic$ (0.49)$ (0.43)
Net loss per common share - diluted$ (0.49)$ (0.43)
Weighted-average number of common shares - basic217,290191,228
Weighted-average number of common shares - diluted217,290191,228

SANA Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 177,054$ 133,517
Marketable securities134,02871,678
Restricted cash3,8323,832
Prepaid expenses and other current assets6,3494,488
Total current assets321,263213,515
Property and equipment, net81,64970,689
Operating lease right-of-use assets71,56574,903
Intangible asset59,19559,195
Goodwill140,627140,627
Other non-current assets7,0786,370
TOTAL ASSETS681,377565,299
Current liabilities:  
Accounts payable6,0954,108
Accrued compensation13,96523,722
Accrued expenses and other current liabilities19,67423,462
Operating lease liabilities13,16713,195
Total current liabilities52,90164,487
Operating lease liabilities, net of current portion92,92290,901
Contingent consideration, net of current portion114,990109,606
Success payment liabilities45,42212,799
Total liabilities306,235277,793
Commitments and contingencies (Note 9)
Stockholders' equity:  
Preferred stock, $0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value; 750,000 shares authorized; 221,286 and 197,857 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively2220
Additional paid-in capital1,820,7011,625,637
Accumulated other comprehensive loss(15)(60)
Accumulated deficit(1,445,566)(1,338,091)
Total stockholders' equity375,142287,506
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 681,377$ 565,299
SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington's disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.
 CEO
 WEBSITEsana.com
 INDUSTRYBiotechnology
 EMPLOYEES424

Sana Biotechnology, Inc. Frequently Asked Questions


What is the ticker symbol for Sana Biotechnology, Inc.? What does SANA stand for in stocks?

SANA is the stock ticker symbol of Sana Biotechnology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sana Biotechnology, Inc. (SANA)?

As of Mon May 13 2024, market cap of Sana Biotechnology, Inc. is 1.75 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SANA stock?

You can check SANA's fair value in chart for subscribers.

What is the fair value of SANA stock?

You can check SANA's fair value in chart for subscribers. The fair value of Sana Biotechnology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sana Biotechnology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SANA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sana Biotechnology, Inc. a good stock to buy?

The fair value guage provides a quick view whether SANA is over valued or under valued. Whether Sana Biotechnology, Inc. is cheap or expensive depends on the assumptions which impact Sana Biotechnology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SANA.